Clinical Trials: Metastatic Cancer

Scottsdale : TGen Clinical Research Services at Scottsdale Healthcare

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Tucson : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Duarte : City of Hope

A Phase 1 Study of ABT-888 in Combination with Carboplatin and Gemcitabine in Subjects with Advanced Solid Tumors

View More »

Greenbrae : Marin Cancer Care

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Los Angeles : Samuel Oschin Comprehensive Cancer Institute

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study of LY3007113 in Patients With Advanced Cancer

Fort Lauderdale : Holy Cross Hospital

14T-MC-JVBB

Savannah : Memorial University Medical Center

SWOG S1201: A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer

Elgin : Sherman Health

SWOG S1201 Phase II Randomized, Pilot Study of FOLFOX Therapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil Versus Irinotecan Hydrochloride and Docetaxel in Patients With Advanced or Metastatic Esophageal Cancer, Gastric Cancer, or Gastroesophageal Junction Cancer

Detriot : Karmanos Cancer Institute

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Lebanon : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Manhasset : Biomedical Research Alliance of New York

Metastatic Cancer to the Brain - Adults

View More »

Great Neck : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

New York : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Huntersville : Carolina BioOncology Institute

Isolation and Culture of Circulating Tumor Cells From Peripheral Blood

Bismarck : St. Alexius Medical Center

A research study for patients with metastatic pancreatic cancer. You may qualify for this study if you have a diagnosis of an advanced type of pancreatic cancer for which standard therapy is not optimal.

Middletown : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study of LY3023414 in Participants With Advanced Cancer

Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study of LY3023414 in Participants With Advanced Cancer

Dallas : Mary Crowley Cancer Research Centers

Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer

San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study of LY3007113 in Patients With Advanced Cancer

Leuven : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Liege : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Wilrijk : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Bordeaux : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Caen Cedex 05 : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

La Roche Sur Yon Cedex 9 : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Marseille : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Nantes Cedex 2 : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

View More »

Pierre Bénite Cedex : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Toulouse : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Seoul : Samsung Medical Center

Phase I Trial of Tanibirumab in Advanced or Metastatic Cancer